Profund Advisors LLC Bio N Tech Se Transaction History

Profund Advisors LLC

$2.67 Billion
Q4 2024

A detailed history of Profund Advisors LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Profund Advisors LLC holds 2,709 shares of BNTX stock, worth $264,046. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,709

Previous 3,381 19.88%

Holding current value

$264,046

Previous $401,000 23.19%

% of portfolio

0.01%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$99.72 - $122.68 $67,011 - $82,440	-672 Reduced 19.88%	2,709 $308,000
Q3 2024 Nov 13, 2024	SELL	$78.36 - $124.66 $39,963 - $63,576	-510 Reduced 13.11%	3,381 $401,000
Q2 2024 Aug 13, 2024	BUY	$80.36 - $102.87 $9,161 - $11,727	114 Added 3.02%	3,891 $312,000
Q1 2024 May 08, 2024	SELL	$88.96 - $112.35 $47,237 - $59,657	-531 Reduced 12.33%	3,777 $348,000
Q4 2023 Feb 14, 2024	BUY	$90.91 - $112.75 $391,640 - $485,727	4,308 New	4,308 $454,000
Q4 2022 Feb 02, 2023	BUY	$118.43 - $186.05 $175,276 - $275,354	1,480 New	1,480 $222,000
Q4 2021 Feb 08, 2022	SELL	$216.64 - $362.52 $732,026 - $1.22 Million	-3,379 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $28,212 - $61,270	137 Added 4.23%	3,379 $922,000
Q2 2021 Aug 12, 2021	BUY	$113.32 - $241.49 $9,518 - $20,285	84 Added 2.66%	3,242 $726,000
Q1 2021 May 14, 2021	BUY	$85.73 - $119.5 $9,858 - $13,742	115 Added 3.78%	3,158 $345,000
Q4 2020 Feb 09, 2021	BUY	$72.71 - $129.54 $221,256 - $394,190	3,043 New	3,043 $248,000

Others Institutions Holding BNTX

# of Institutions

363

Shares Held

39.6M

Call Options Held

3.01M

Put Options Held

2.01M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $23.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Profund Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Profund Advisors LLC with notifications on news.

Account

Profund Advisors LLC Bio N Tech Se Transaction History